Nautilus Biotechnolgy, Inc.

NASDAQ: NAUT · Healthcare · Biotechnology

PublicHQ Seattle, WA · KingCIK 0001808805Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 54DQ —GM —SS 53

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

$190.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$59.0M

Employees

127

as of 2026-08-13

Market cap

$114.5M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$59.0M-$59.0M2025

Operating income-$576.0k-$576.0k2020

Total assets$191.1M$191.1M2025

Liabilities$34.1M$34.1M2025

Equity$157.0M$157.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Nautilus Biotechnolgy, Inc.’s financial profile?

Nautilus Biotechnolgy, Inc. earned -$59.0M in FY2025 net income.

Peers · Healthcare

NervGen Pharma Corp. Common stock——Milestone Pharmaceuticals Inc.——Polaryx Therapeutics, Inc. Common Stock——enGene Holdings Inc.——Biomea Fusion, Inc.——Park Dental Partners, Inc. Common Stock——

Neighbors

King →

Microsoft Corporation$281.7B89A Amazon.com, Inc.$716.9B87A Costco Wholesale Corporation$275.2B84B+T-Mobile US, Inc.$88.3B84B+Starbucks Corporation$37.2B74B PACCAR Inc$28.4B73B

Key facts

CEOSujal Patel

SectorHealthcare

IndustryBiotechnology

HeadquartersSeattle, WA

ExchangeNASDAQ: NAUT

Employees127

IPO date2020-08-07

Latest filings

10-Q2026-07-28 8-K2026-07-28 8-K2026-06-18 10-Q2026-04-28 8-K2026-04-28 DEF 14A2026-04-28 8-K2026-02-26 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.